Fusion Polypeptide Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for Alzheimer's disease face challenges in achieving sufficient blood-brain barrier penetration, limiting the efficacy of biologics in treating neurodegenerative diseases like Alzheimer's due to the barrier's restrictive nature, which prevents efficient uptake into the brain.
Innovation Solution
A fusion polypeptide comprising Cystatin C (CysC) protein, a first linker, Human Serum Albumin, a second linker, and a modified TAT amino acid sequence as a cell penetrating peptide is developed to facilitate crossing the blood-brain barrier, allowing for the systemic administration of a therapeutically effective dose to treat Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologics are used to treat Alzheimer's disease, then therapeutic efficacy is improved, but blood-brain barrier penetration is insufficient
Solution Approach 1:
The patent uses a cell-penetrating peptide (CPP) as an intermediary component to facilitate the transport of biologics across the blood-brain barrier. The CPP is conjugated to the biologic through a linker, creating a fusion molecule that can penetrate the BBB and deliver the therapeutic biologic to the brain, thereby resolving the penetration limitation while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates a composite molecular structure by conjugating a biologic (such as an antibody or protein) with a cell-penetrating peptide through a linker. This composite fusion molecule combines the therapeutic properties of the biologic with the BBB-penetrating capability of the CPP, enabling both brain delivery and therapeutic function.
2Reliability
If the size of therapeutic molecules is increased to improve efficacy, then therapeutic power is enhanced, but blood-brain barrier penetration ability deteriorates
Solution Approach 1:
The cell-penetrating peptide serves as a size-reduction intermediary, allowing large biologics to effectively navigate the blood-brain barrier by attaching to a small CPP component. The CPP acts as a delivery vehicle that can transport the larger biologic across the BBB despite size constraints.
Solution Approach 2:
The patent segments the therapeutic molecule into distinct functional components: a biologic component for therapeutic efficacy, a linker for connection, and a cell-penetrating peptide for BBB delivery. This segmentation allows each component to perform its specialized function while working together as a unified therapeutic system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion polypeptide effectively reduces amyloid beta plaque deposition and hyperphosphorylated Tau levels in the brain, providing neuroprotection and potential therapeutic benefits for Alzheimer's disease.
Implementation Method 1
Cell-penetrating peptide (CPP)-mediated drug delivery is one way to enhance brain delivery. Studies in rodents in vivo revealed that conjugation of HIV-1 trans-activating transcriptor (TAT), the most well-known CPP, with a biomolecule results in a construct that was able to facilitate the delivery of biomacromolecules across the BBB
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application discloses a method for treating a protein deficiency in the central nervous system of a subject in need thereof, comprising systemically administering to the subject a therapeutically effective dose of a fusion polypeptide comprising the first protein, wherein the fusion polypeptide comprises: (a) the first protein; (b) a second protein that provides extended circulation-lifetime in vivo and (c) blood brain barrier crossing facilitating peptide; wherein the fusion polypeptide crosses the blood brain barrier (BBB).